Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virtual Meet...
May 19 2021 - 8:05AM
Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical
company pioneering differentiated therapies for patients with liver
and gastrointestinal diseases, today announced that it will present
new preclinical data demonstrating the synergistic effect of
MET642, a farnesoid X receptor (FXR) agonist, when combined with
tofacitinib, a JAK inhibitor, in improving inflammatory bowel
disease (IBD) at Digestive Disease Week (DDW) 2021. The virtual
meeting is being held from May 21-23, 2021.
“Building on our previous monotherapy findings with FXR
agonists, we now demonstrate that combining low doses of MET642 and
tofacitinib led to robust improvement in a murine colitis model,”
said Hubert C. Chen, M.D., chief medical officer, Metacrine. “Our
FXR product candidates offer a targeted, anti-inflammatory, oral
therapy that is not immunosuppressive and can be used in
combination regimens, potentially affording unique treatment
options for patients with IBD.”
The Company’s poster is:
Title - Combination of FXR Agonist MET642 with
Tofacitinib Exhibits Synergistic Effects in Improving Colitis in
Adoptive T-Cell Transfer IBD Model
ePoster Number – Fr141
Presentation Date and Time: May 21, 2021
(12:15pm ET to 1:00pm ET)
About Metacrine
Metacrine, Inc. is a clinical-stage biopharmaceutical company
building a pipeline of differentiated therapies to treat liver and
gastrointestinal diseases. Metacrine has developed a proprietary
farnesoid X receptor (FXR) platform utilizing a unique chemical
scaffold, which has demonstrated an improved therapeutic profile in
clinical trials. The Company’s two product candidates, MET409 and
MET642, are currently being investigated in clinical trials as
potential new treatments for NASH. MET409 has completed a 12-week
monotherapy trial in patients with NASH and is being evaluated in a
12-week combination trial with empagliflozin in patients with both
NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1
trial in healthy volunteers and is being evaluated in a 16-week
monotherapy trial in patients with NASH. To learn more, visit
www.metacrine.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, statements about plans for
initiating future clinical trials and studies; statements regarding
the therapeutic potential of MET642; the differentiated nature of
Metacrine’s FXR program and product candidates; the potential for
its FXR product candidates to be used in combination therapies; and
the potential for its FXR product candidates to be therapies for
IBD. Words such as “may,” “will,” “expect,” “plan,” “aim,”
“projected,” “likely,” “anticipate,” “estimate,” “intend,”
“potential,” “prepare,” “perceived,” “believes” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to
identify forward-looking statements. These forward-looking
statements are based on Metacrine’s expectations and assumptions
that may never materialize or prove to be incorrect. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from those projected in any
forward-looking statements due to numerous risks and uncertainties,
including but not limited to: the risk that existing preclinical
and clinical data may not be predictive of the results of ongoing
or later clinical trials; risks and uncertainties regarding
regulatory approvals for MET409 or MET642; potential delays in
initiating, enrolling or completing any clinical trials; potential
adverse side effects or other safety risks associated with
Metacrine’s product candidates; competition from third parties that
are developing products for similar uses; and Metacrine’s ability
to obtain, maintain and protect its intellectual property.
Information regarding the foregoing and additional risks may be
found in the section entitled “Risk Factors” in Metacrine’s Annual
Report on Form 10-K filed with the Securities and Exchange
Commission (the “SEC”) on March 18, 2021, and in Metacrine’s other
filings with the SEC. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Except as required by law, Metacrine assumes
no obligation to update any forward-looking statements
contained herein to reflect any change in expectations, even as new
information becomes available.
Investor & Media Contact
Steve Kunszabo
Metacrine, Inc.
+1 (858) 369-7892
skunszabo@metacrine.com
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Sep 2023 to Sep 2024